Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04724239	TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma	Fase Fase 2	Date Added 2021-01-26	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas chidamide, IBI305, Sintilimab	Etiquetas MSS/ MMRp
NCT ID NCT03093116	TitleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Fase Phase 1, Phase 2	Date Added 2017-03-28	Ubicación California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Bélgica Canadá China Dinamarca Francia Alemania Hong Kong Hungary Italia Japón Corea, República de Países Bajos Polonia Singapur España Taiwán Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Oral repotrectinib (TPX-0005)	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05677113	TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver	Fase Fase 2	Date Added 2023-01-10	Ubicación Canadá	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Placebo, QBECO	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Fase Fase 1	Date Added 2021-11-04	Ubicación California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas NX-1607	Etiquetas MSS/ MMRp
NCT ID NCT06218914	TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation	Fase Fase 1	Date Added 2024-01-23	Ubicación California, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06792695	TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	Fase Fase 2	Date Added 2025-03-25	Ubicación Arizona, United States California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New York, United States Ohio, United States Texas, United States Australia Canadá China Francia Alemania Italia Corea, República de España Taiwán Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT04008030	TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )	Fase Fase 3	Date Added 2019-07-05	Ubicación California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Bélgica Brasil Canadá Chile China Czechia Dinamarca Francia Alemania Greece Ireland Italia Japón Países Bajos Noruega Puerto Rico Romania España Turkey Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin	Etiquetas MSI-H/ MMRd
NCT ID NCT05328908	TitleUn estudio de combinación de dosis fija de nivolumab-relatlimab frente a regorafenib o TAS-102 en participantes con cáncer colorrectal metastásico de última línea	Fase Fase 3	Date Added 2022-04-14	Ubicación Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Bélgica Canadá Chile China Czechia Francia Alemania Italia Japón Corea, República de Países Bajos Polonia Puerto Rico Singapur España Suecia Suiza Taiwán	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Etiquetas MSS/ MMRp
NCT ID NCT04426669	TitleEstudio de cánceres gastrointestinales metastásicos tratados con linfocitos infiltrantes tumorales en los que se inhibe el gen que codifica el punto de control inmunitario intracelular CISH mediante ingeniería genética CRISPR.	Fase Phase 1, Phase 2	Date Added 2020-06-11	Ubicación Minnesota, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT01351103	TitleA Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Fase Fase 1	Date Added 2011-05-10	Ubicación California, United States Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canadá Francia Alemania Italia Países Bajos España	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas LGK974, PDR001	Etiquetas MSS/ MMRp

Showing 251 to 260 of 299 entries